Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001231978 | SCV001404517 | pathogenic | not provided | 2023-11-24 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 5 of the SLC12A3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SLC12A3 are known to be pathogenic (PMID: 20848653, 22009145, 25841442). This variant is present in population databases (no rsID available, gnomAD 0.002%). Disruption of this splice site has been observed in individuals with Gitelman syndrome (PMID: 12772080, 18391953). ClinVar contains an entry for this variant (Variation ID: 958758). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
MGZ Medical Genetics Center | RCV001828849 | SCV002580033 | likely pathogenic | Familial hypokalemia-hypomagnesemia | 2022-05-31 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001828849 | SCV002788953 | pathogenic | Familial hypokalemia-hypomagnesemia | 2021-07-29 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001828849 | SCV002089335 | pathogenic | Familial hypokalemia-hypomagnesemia | 2020-11-25 | no assertion criteria provided | clinical testing |